Compared with existing liver cancer treatment drugs, BSCAs have the advantage of being derived from natural products, with minimal toxicity to normal cells and a low extraction cost, and BSCAs act on JAK2/STAT3 targets to inhibit the proliferation of liver cancer cells, providing a new direction for the development of liver cancer drugs. This evidence concerns the gene STAT3 and liver cancer.